Access TOC
Download Data
November 2024
The global cardiac biomarkers market size is calculated at USD 21.27 billion in 2024, grew to USD 24.39 billion in 2025, and is projected to reach around USD 83.54 billion by 2034. The market is expanding at a CAGR of 14.66% between 2024 and 2034. The increasing incidences of heart attacks, growing demand for point-of-care diagnostics, and rise in preventive care drive the market.
Unlock Infinite Advantages: Subscribe to Annual Membership
Cardiac biomarkers are enzymes, proteins, or hormones released in the bloodstream when the heart is damaged or stressed. A cardiac biomarker test is performed to diagnose acute coronary syndrome and cardiac ischemia by measuring the levels of cardiac biomarkers. The cardiac biomarkers include troponin (I and T), creatinine kinase (CK), CK-MB, and myoglobin. An increase in one or more of these biomarkers in the blood can identify potential heart damage in a patient. This allows for rapid and accurate diagnosis and suitable treatment for their condition.
The increasing incidences of heart attacks increase the demand for testing cardiac biomarkers in patients suffering from chest pain and other symptoms. Cardiovascular disease is the leading cause of premature deaths globally, necessitating preventive care. The growing demand for point-of-care diagnostics also boost the market. Cardiac biomarker tests can also significantly reduce the total healthcare expenditure.
AI is driving an exponential development in technology that is defining new boundaries in cardiovascular care. These innovations include new digital native biomarkers of disease, innovative diagnostic modalities, and high-performing systems for assessing the quality of therapy and forecasting clinical outcomes. Artificial intelligence (AI) can significantly revolutionize the way cardiac biomarkers are monitored in a patient. Several researchers are currently developing AI and machine learning (ML) methodologies to improve the diagnostic ability of cardiac biomarker tests.
AI can enable improved personalized treatments through predictive analysis and deep phenotyping. AI/ML algorithms can be employed to gather whole genome and whole exome sequencing data for statistical and prognostic analysis of cardiac disorders. Additionally, sensors within smartphone technology and data transfer technology can assess digital cardiac biomarkers. Hence, AI can result in rapid, accurate, and reproducible results.
Rising Demand for Point-of-Care Diagnostics: The point-of-care (PoC) diagnostics allow for quick results at the patient’s bedside or within the emergency departments, facilitating disease diagnosis, monitoring, and management. The global COVID-19 pandemic and suitable regulatory framework increased the demand and use of PoC diagnostics. The US Food and Drug Administration (FDA) also supports developers who present the FDA with new, innovative tests. The Centers for Disease Control and Prevention (CDC) also provides free training and tools to help people learn the basics of performing PoC tests. Additionally, favorable government policies and increasing investments support PoC development. Furthermore, the integration of advanced technologies such as AI and sensors enhances the diagnostic efficiency of the test, suggesting accurate and personalized treatments. Hence, the growing demand for PoC diagnostics drives the cardiac biomarkers market.
Lack of Specificity and Variations: The major challenge of the cardiac biomarkers market includes the lack of specificity of certain biomarkers. Certain cardiac biomarkers lack specificity as they can be elevated in multiple diseases other than CVDs. This could result in false detection of the disease. Another major challenge of the market includes variations in the biomarker levels among different individuals due to gender, age, and other factors. Hence, universal cut-off values cannot be established. These challenges can restrict the use of cardiac biomarkers for testing CVDs.
Growing Research and Development: The escalating global burden of CVDs and advancements in biotechnology and diagnostic tools have fueled intensive research and development (R&D) in this field, thereby presenting future cardiac biomarkers market growth opportunities. Several researchers are investigating the role of cardiac biomarkers in the early detection of heart diseases. Novel biomarkers such as microRNAs, genetic variants, metabolomics markers, etc., have been researched and could revolutionize CVD diagnosis and management. Also, well-proven markers are investigated for other pathophysiological pathways, including inflammation, oxidative stress, and fibrosis, that are pivotal in cardiovascular disease. Additionally, biomarkers are developed to eventually reduce the cost of testing of CVDs. Novel devices have been invented to detect cardiac biomarkers precisely and in less time. Hence, biomarkers are the most rapidly evolving field, resulting in novel findings for better treatment outcomes.
By type, the troponin segment held a dominant presence in the cardiac biomarkers market in 2023. Troponin is the most commonly used biomarker as it is more sensitive and specific for heart attacks. It releases into the bloodstream soon after a heart attack and remains in the blood for up to two weeks, helping healthcare providers to detect heart attacks. Troponin can be measured in two forms: troponin T and troponin I. In addition, the availability of high-sensitivity troponin tests can detect minute levels of troponin. The American Heart Association (AHA) has also released guidelines suggesting the use of troponin over other cardiac biomarkers.
By type, the BNP and NT-proBNP segment is expected to grow at the fastest rate in the market during the forecast period. These biomarkers are specifically used to diagnose and rule out heart failure. The rising incidences of heart failure and the need for early detection augment the segment’s growth. According to the Swedish Government, around 23,200 acute myocardial infarction cases were reported in Sweden in 2022 at a rate of 288 cases per 100,000 population.
By application, the acute coronary syndrome segment led the global cardiac biomarkers market in 2023. The rising incidences of acute coronary syndrome and its severity boost the segment’s growth. Acute coronary syndrome (ACS) is a potentially life-threatening condition characterized by the sudden onset of persistent pain, shortness of breath, nausea, perfusion, and dizziness. Hence, biomarkers are used for ACS diagnosis, risk stratification, and prognosis assessment to derive effective treatment strategies.
By application, the congestive heart failure segment is estimated to grow fastest in the cardiac biomarkers market over the coming years. Biomarkers such as natriuretic peptides, ST2, and hsTn1 are commonly used to predict the pathophysiological processes involved in congestive heart failure (CHF). Apart from this, genetic testing, including miRNA, also accurately predicts the disease. The rising incidences of CHF and growing R&D involving the discovery of novel biomarkers for CHF conditions promote the segment’s growth.
By end-use, the laboratory testing segment registered its dominance over the global cardiac biomarkers market in 2023. The laboratory consists of all essential instruments and reagents for conducting biomarker tests. The segment’s growth is also attributed to the presence of skilled professionals in laboratories and suitable infrastructure. A greater number of patients report to a healthcare professional in case of experiencing symptoms related to CVDs. Laboratory testing provides reliable and precise health problem results, while other tests give a general idea. Hence, laboratories are widely preferred among patients.
By end-use, the point-of-care testing segment is anticipated to grow with the highest CAGR in the market during the studied years. The increasing number of patients in emergency departments due to cardiac arrest, favorable government policies, and technological advancements potentiate the segment’s growth. PoC provides faster results compared to laboratory testing, facilitating healthcare professionals in the decision-making process. Furthermore, the rising geriatric population increases the demand for PoC diagnostics.
North America held the largest share of the cardiac biomarkers market in 2023. The rising incidences of cardiovascular diseases, increasing investments, the presence of key players, and favorable government policies drive the market. In the US, an estimated 1.2 million individuals are hospitalized due to acute coronary syndrome annually. It is estimated that more than 750,000 people in Canada live with heart failure.
Recently, the Biomedical Advanced Research and Development Authority (BARDA) announced a strategic five-year plan (2022-2026) to develop and procure medical countermeasures addressing public health and medical consequences. As part of the plan, BARDA ventures will work with its non-profit partner to raise a $500 million global health security impact fund. Additionally, the Minister of Health of the Canadian Government announced a funding of $5 million to support a new national research network that will focus on improving the prevention, diagnosis, treatment, and care of heart failure across the nation.
Asia-Pacific is projected to host the fastest-growing cardiac biomarkers market in the coming years. The rising geriatric population, increasing incidences of cardiac disorders, growing research and development, and increasing investments & collaborations drive the market. In China, it is estimated that more than 330 million currently have CVD, accounting for 11.39 million people with coronary heart disease and 8.9 million people with heart failure. In India, around 32,457 people died from heart attacks in 2022, accounting for a 12.5% increase in heart attack cases in 2022 from the previous year. Similarly, in Japan, heart disease is the second-leading cause of death, responsible for 14.8% of deaths in 2022. This necessitates the demand for cardiac biomarker testing in the region for early detection and prognosis.
Professor Damian Corrigan, Principal Investigator and Director of the Center for Advanced Measurement Research and Health Translation, Strathclyde, announced that they are working on a new technology to develop a rapid, low-cost sensor to detect heart attack victims more quickly. He stated that cardiac biomarkers can support an early and accurate diagnosis that will empower paramedics, community healthcare practitioners, and first responders to make the best decisions for delivering healthcare to patients and help save lives.
By Type
By Application
By End-Use
By Region
November 2024
November 2024
Annual Access, Limitless Research! Unlock all market research reports with our annual subscription. Stay on top of market trends and crucial insights year-round!
2500+
Client Queries in 20235000+
Insights Published60+
Consulting Projects Per Year40+
Analysts